Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 infection may be associated with a prothrombotic state, predisposing patients for a progressive disease course. We investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression.
METHODS: Adults (N = 497) with mild COVID-19 symptoms and at high risk for COVID-19 progression based on age, body mass index, or comorbidity were randomized 1:1 to either daily oral rivaroxaban 10 mg (N = 246) or placebo equivalent (N = 251) for 21 days and followed to day 35. Primary end points were safety and progression. Absolute difference in progression risk was assessed using a stratified Miettinen and Nurminen method.
RESULTS: The study was terminated after 497 of the target 600 participants were enrolled due to a prespecified interim analysis of the first 200 participants that crossed the futility boundary for the primary efficacy end point in the intent-to-treat population. Enrollees were 85% aged <65 years; 60% female; 27% Hispanic, Black, or other minorities; and 69% with ≥2 comorbidities. Rivaroxaban was well tolerated. Disease progression rates were 46 of 222 (20.7%) in rivaroxaban vs 44 of 222 (19.8%) in placebo groups, with a risk difference of -1.0 (95% confidence interval, -6.4 to 8.4; P = .78).
CONCLUSIONS: We did not demonstrate an impact of rivaroxaban on disease progression in high-risk adults with mild COVID-19. There remains a critical public health gap in identifying scalable effective therapies for high-risk people in the outpatient setting to prevent COVID-19 progression.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
---|---|
Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 75(2022), 1 vom: 24. Aug., Seite e473-e481 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ananworanich, Jintanat [VerfasserIn] |
---|
Links: |
---|
Themen: |
9NDF7JZ4M3 |
---|
Anmerkungen: |
Date Completed 29.08.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/cid/ciab813 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330657453 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM330657453 | ||
003 | DE-627 | ||
005 | 20231225211750.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/cid/ciab813 |2 doi | |
028 | 5 | 2 | |a pubmed24n1102.xml |
035 | |a (DE-627)NLM330657453 | ||
035 | |a (NLM)34523673 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ananworanich, Jintanat |e verfasserin |4 aut | |
245 | 1 | 0 | |a Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019 |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.08.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 infection may be associated with a prothrombotic state, predisposing patients for a progressive disease course. We investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression | ||
520 | |a METHODS: Adults (N = 497) with mild COVID-19 symptoms and at high risk for COVID-19 progression based on age, body mass index, or comorbidity were randomized 1:1 to either daily oral rivaroxaban 10 mg (N = 246) or placebo equivalent (N = 251) for 21 days and followed to day 35. Primary end points were safety and progression. Absolute difference in progression risk was assessed using a stratified Miettinen and Nurminen method | ||
520 | |a RESULTS: The study was terminated after 497 of the target 600 participants were enrolled due to a prespecified interim analysis of the first 200 participants that crossed the futility boundary for the primary efficacy end point in the intent-to-treat population. Enrollees were 85% aged <65 years; 60% female; 27% Hispanic, Black, or other minorities; and 69% with ≥2 comorbidities. Rivaroxaban was well tolerated. Disease progression rates were 46 of 222 (20.7%) in rivaroxaban vs 44 of 222 (19.8%) in placebo groups, with a risk difference of -1.0 (95% confidence interval, -6.4 to 8.4; P = .78) | ||
520 | |a CONCLUSIONS: We did not demonstrate an impact of rivaroxaban on disease progression in high-risk adults with mild COVID-19. There remains a critical public health gap in identifying scalable effective therapies for high-risk people in the outpatient setting to prevent COVID-19 progression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a infection | |
650 | 4 | |a pneumonia | |
650 | 4 | |a rivaroxaban | |
650 | 7 | |a Rivaroxaban |2 NLM | |
650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
700 | 1 | |a Mogg, Robin |e verfasserin |4 aut | |
700 | 1 | |a Dunne, Michael W |e verfasserin |4 aut | |
700 | 1 | |a Bassyouni, Mohamed |e verfasserin |4 aut | |
700 | 1 | |a David, Consuela Vera |e verfasserin |4 aut | |
700 | 1 | |a Gonzalez, Erika |e verfasserin |4 aut | |
700 | 1 | |a Rogalski-Salter, Taryn |e verfasserin |4 aut | |
700 | 1 | |a Shih, Heather |e verfasserin |4 aut | |
700 | 1 | |a Silverman, Jared |e verfasserin |4 aut | |
700 | 1 | |a Medema, Jeroen |e verfasserin |4 aut | |
700 | 1 | |a Heaton, Penny |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 75(2022), 1 vom: 24. Aug., Seite e473-e481 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
773 | 1 | 8 | |g volume:75 |g year:2022 |g number:1 |g day:24 |g month:08 |g pages:e473-e481 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab813 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 75 |j 2022 |e 1 |b 24 |c 08 |h e473-e481 |